- Home
- CMMB vs TENX Comparison
CMMB vs TENX Comparison
Compare CMMB & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- TENX
- Stock Information
- Founded
- CMMB 2004
- TENX 1967
- Country
- CMMB Israel
- TENX United States
- Employees
- CMMB N/A
- TENX N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- TENX Health Care
- Exchange
- CMMB Nasdaq
- TENX Nasdaq
- Market Cap
- CMMB 15.8M
- TENX 11.4M
- IPO Year
- CMMB N/A
- TENX N/A
- Fundamental
- Price
- CMMB $1.25
- TENX $3.40
- Analyst Decision
- CMMB Strong Buy
- TENX Strong Buy
- Analyst Count
- CMMB 3
- TENX 2
- Target Price
- CMMB $5.67
- TENX $30.00
- AVG Volume (30 Days)
- CMMB 178.8K
- TENX 27.5K
- Earning Date
- CMMB 11-07-2024
- TENX 11-11-2024
- Dividend Yield
- CMMB N/A
- TENX N/A
- EPS Growth
- CMMB N/A
- TENX N/A
- EPS
- CMMB N/A
- TENX N/A
- Revenue
- CMMB N/A
- TENX N/A
- Revenue This Year
- CMMB N/A
- TENX N/A
- Revenue Next Year
- CMMB N/A
- TENX N/A
- P/E Ratio
- CMMB N/A
- TENX N/A
- Revenue Growth
- CMMB N/A
- TENX N/A
- 52 Week Low
- CMMB $0.42
- TENX $2.77
- 52 Week High
- CMMB $2.55
- TENX $61.20
- Technical
- Relative Strength Index (RSI)
- CMMB 33.68
- TENX 42.55
- Support Level
- CMMB $1.29
- TENX $3.28
- Resistance Level
- CMMB $1.59
- TENX $3.54
- Average True Range (ATR)
- CMMB 0.17
- TENX 0.20
- MACD
- CMMB -0.05
- TENX -0.01
- Stochastic Oscillator
- CMMB 2.00
- TENX 26.42
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.